Dr. Ferguson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1465 S Grand Blvd
Saint Louis, MO 63104Phone+1 314-577-5638Fax+1 314-268-4081
Summary
- Dr. William Ferguson is a Pediatric Hematology and Oncology specialist based in Saint Louis, MO. His areas of interest include bone and soft tissue sarcomas, neuroblastoma, bone marrow transplantation, and use of precision medicine for treatment of pediatric malignancies. He graduated from New York University School of Medicine in 1982 and completed his pediatric residency and pediatric hematology-fellowship at Massachusetts General Hospital. He has participated in multiple clinical trials through the Children's Oncology Group and the Beat Childhood Cancer Research Consortium. Dr. Ferguson is a Fellow of the American Academy of Pediatric, and a member of the American Society of Pediatric Hematology-Oncology and the American Society of Clinical Oncology.
Education & Training
- Massachusetts General HospitalResidency, Pediatrics, 1982 - 1986
- New York University School of MedicineClass of 1982
Certifications & Licensure
- MO State Medical License 2004 - 2026
- IL State Medical License 2006 - 2023
- MA State Medical License 1984 - 2009
- RI State Medical License 1996 - 2004
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Fellow (FAAP) American Academy of Pediatrics
Clinical Trials
- Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
- Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Start of enrollment: 2004 Sep 04
- Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Start of enrollment: 2004 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsA pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.Jacqueline M Kraveka, Elizabeth C Lewis, Genevieve Bergendahl, William Ferguson, Javier Oesterheld
Cancer Reports. 2022-11-01 - 7 citationsA Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma.Giselle Saulnier-Sholler, Dan G Duda, Genevieve Bergendahl, David Ebb, Matija Snuderl
Clinical Cancer Research. 2022-09-15 - 11 citationsGenomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune EvasionSara A. Byron, William P.D. Hendricks, Abhinav Nagulapally, Jacqueline M. Kraveka, William S. Ferguson
Cancer Research. 2021-10-05
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: